Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Breast Neoplasms 3135Neoplasms 2480Carcinoma, Non-Small-Cell Lung 1877Prostatic Neoplasms 1635Colorectal Neoplasms 1422Lung Neoplasms 1308Multiple Myeloma 935Neoplasm Metastasis 927Leukemia, Myeloid, Acute 883Pancreatic Neoplasms 861Ovarian Neoplasms 811Melanoma 792Carcinoma, Hepatocellular 739Stomach Neoplasms 649Brain Neoplasms 638Squamous Cell Carcinoma of Head and Neck 637Recurrence 637Head and Neck Neoplasms 606Glioblastoma 569Lymphoma 550Uterine Cervical Neoplasms 544Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 514Carcinoma, Renal Cell 504Hematologic Neoplasms 464Endometrial Neoplasms 463Urinary Bladder Neoplasms 462Colonic Neoplasms 446Lymphoma, Non-Hodgkin 437Sarcoma 435

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Nivolumab 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × 1 year × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04106414 2025-10-14

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡